Question-and-Answer Session
Operator
(Operator Instructions). Your first question comes from the line of Ram Selvaraju of Hapoalim Securities.
Ram Selvaraju - Hapoalim Securities
A couple of financial related items, first of all, can you please give me the number of shares outstanding as of the end of the quarter, please?
Jay File
Approximately $61.2 million.
Ram Selvaraju - Hapoalim Securities
Can you give me a number for the share-based compensation in the quarter, please?
Jay File
Total share-based compensation for the quarter was $3 million.
Ram Selvaraju - Hapoalim Securities
With respect to the 8-K that was filed regarding the recent renegotiation of the Isis Innovation licensing agreement, could you give us a bit more color as to what the revised royalty obligations are and whether this represents a meaningful change from what was previously in place?
Harry Hixson
I think the only thing we would say about royalties was that basically, the last year of the license agreement, we agreed to double the royalty payment. That's in recognition of approximately one-year delay in the program.
Ram Selvaraju - Hapoalim Securities
With respect to the revised milestones, these have not changed in a significantly meaningful manner. In other words, we should not be looking at this revised agreement as being materially impactful to overall assumptions concerning the valuation of the technology and how it pertains to noninvasive prenatal testing?
Harry Hixson
I think that's a fair assumption.
Ram Selvaraju - Hapoalim Securities
With respect to the ongoing clinical trials that were listed in the press release you issued today, are any of these studies that were actually begun in the third quarter?
Harry Hixson
No, I don't believe so. I believe we were collecting samples before the third quarter.
Ram Selvaraju - Hapoalim Securities
With respect to the R&D study, which is apparently now being called the CHARMM study, can you disclose what status that is at right now? Are all of these studies currently just undergoing sample collection or are any of them in the analysis phase?
Harry Hixson
They are all in the sample collection phase.
Ram Selvaraju - Hapoalim Securities
Then the final thing would be with respect to the women and infants validation study, which is the independent party that is currently carrying that out?
Harry Hixson
We're just collecting samples at this point.
Ram Selvaraju - Hapoalim Securities
That would be destined for a verification conducted by an external party, is that correct?
- To read the full transcript on Seeking Alpha, click here »
